SCHEMBL13097082

SCHEMBL13097082

Cc1ccc(F)c(NC(=O)Nc2cccc(-c3cncc4c3cnn4C)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.57
FLT3 P36888 8/20 0.57
KIT P10721 7/20 0.57
CSF1R P07333 5/20 0.57
FLT1 P17948 5/20 0.57
FLT4 P35916 5/20 0.57
LYN P07948 4/20 0.57
BLK P51451 4/20 0.57
LCK P06239 3/20 0.57
AURKA O14965 3/20 0.57
MAPK13 O15264 3/20 0.57
DYRK3 O43781 3/20 0.57
ROCK2 O75116 3/20 0.57
RPS6KA5 O75582 3/20 0.57
RET P07949 3/20 0.57
MET P08581 3/20 0.57
FGFR1 P11362 3/20 0.57
RPS6KB1 P23443 3/20 0.57
EPHA2 P29317 3/20 0.57
AXL P30530 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848792 0.89 KDR (0.70) KDRFLT3KITCSF1RFLT1
SCHEMBL13097009 0.86 LCLAT1 (0.49) KDRFLT3KITCSF1RFLT1
SCHEMBL12322989 0.84 KDR (0.60) KDRFLT3KITCSF1RFLT1
SCHEMBL1499160 0.83 KDR (0.58) KDRFLT3KITCSF1RFLT1
SCHEMBL4232674 0.81 KDR (0.82) KDRFLT3KITCSF1RFLT1
SCHEMBL13096661 0.81 NTRK1 (0.61) KDRFLT3KITCSF1RFLT1
SCHEMBL13873380 0.80 KDR (0.68) KDRFLT3KITCSF1RFLT1
SCHEMBL3847135 0.79 KIT (0.57) KDRFLT3KITCSF1RFLT1
SCHEMBL3845215 0.79 KDR (0.66) KDRFLT3KITCSF1RFLT1
SCHEMBL3845211 0.78 KDR (0.58) KDRFLT3KITCSF1RFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100261730-A1 ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261730-A1 ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME ALK, ALKBH3, EDNRB KDR 6/4885FLT3 409/4885KIT 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.